Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

LYTENAVA (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in th ...

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt ...

Cash and Cash Equivalents: As of March 31, 2025, Kalaris had cash and cash equivalents of $101.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024. The increase ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.

Q1 2025 Earnings Call Transcript May 7, 2025 EyePoint Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.65 EPS, expectations were $-0.65. Operator: Good morning. My ...

Subcutaneous administration generally safe and well-tolerated across multiple doses>80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in ...

Researchers reviewed the need for supplemental aflibercept injections and overall treatment burden in eyes being treated for ...

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.